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The Adrenergic-Fatty Acid Load in Heart Failure
Lionel H. Opie, MD, DPHIL, DSC,* Juhani Knuuti, MD, PHD†
Cape Town, South Africa; and Turku, Finland
The hypothesis proposed is that heart failure (HF) is associated with a reactive hyperadrenergic state that in-
creases circulating plasma free fatty acids (FFAs), which leads to impaired glucose metabolism and insulin resis-
tance. We propose that increased FFA-induced mitochondrial uncoupling and substantial oxygen wastage is
closely associated with the generation of reactive oxygen species, inflammatory markers, and the development
of insulin resistance. The therapeutic aims of metabolic therapy are as follows: 1) to decrease hyperadrenergic
drive; 2) to inhibit lipotoxicity and glucotoxicity; and 3) to increase glucose uptake by muscle. These aims are
achieved, respectively, by the following: 1) the use of beta-adrenergic blockade and all measures that relieve the
mechanical load on the heart; 2) the use of drugs that inhibit fatty acid oxidation (trimetazidine, perhexiline),
although without clinical evidence that the heart is their major site of action in HF; and 3) increase of the trans-
port of glucose into the cells by exercise and metformin. Of these measures, only data concerning the reduction
of mortality as the result of exercise are available. Of all the other measures, there are substantial positive data
on the use of trimetazidine that demonstrate metabolic and clinical benefit with almost no side effects, but data
from a large outcome trial are lacking. Our data suggest a major extracardiac site of trimetazidine action.
Ranolazine, which inhibits the late sodium inward current, requires testing in human HF. Insulin to reduce hyper-
glycemia and FFAs is untested in HF, with incretins such as glucagon-like peptide-1 on the horizon. Other future
therapies may include malonyl-coenzyme A regulators to inhibit fatty acid oxidation, fish oil omega-3, and activa-
tors of protein kinase C-epsilon. (J Am Coll Cardiol 2009;54:1637–46) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.024t
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oeart failure (HF) may be regarded as failure of myocardial
ontraction and/or relaxation that is accompanied by a
eurohumoral reaction, the therapy of which has been
trikingly successful and has led to the routine use of
ngiotensin-converting enzyme inhibitors and beta-
lockers. Fluid overload is alleviated by the use of diuretics.
hese standard therapies indirectly improve the metabolism
f the heart by decreasing pre-load, afterload, and heart rate,
ll of which diminish the mechanical workload, thereby
educing the myocardial oxygen demand and lessening the
equirement for mitochondrial production of adenosine
riphosphate (ATP).
In addition, there are specific major metabolic abnormal-
ties, both cardiac and extracardiac, that are susceptible to
etabolically based therapy (1). We propose that the core of
hese abnormalities lies in the compensatory hyperadrener-
ic state that develops in HF (2) with elevation of blood free
atty acid (FFA) levels (3), derived from adipose tissue
4–6). These excess circulating FFAs block the uptake of
lucose by muscle (7), thereby increasing gluconeogenesis,
hich in turn may promote hyperglycemia if insulin secre-
rom the *Hatter Cardiovascular Research Institute, Department of Medicine,
aculty of Health Sciences, University of Cape Town, Observatory, Cape Town,
outh Africa; and the †Turku PET Centre, University of Turku, Turku, Finland.c
Manuscript received April 28, 2009; revised manuscript received July 15, 2009,
ccepted July 27, 2009.ion is limited (8). These changes in glucose metabolism,
hen combined with the high FFA and the resultant
timulation of the inflammatory system (6), could constitute
pattern of metabolic dysregulation that is a major step on
he route to insulin resistance (1). Excess FFA also can
ause abnormalities of mitochondrial function, including
xcessive mitochondrial metabolism with the formation of
eactive oxygen species (ROS), oxygen wastage (9–11), and
ncreased mitochondrial and cytosolic calcium and sodium,
ll of which may further impair myocardial function with
xpected adverse effects on the already-failing heart (12).
hus, a process starting as HF due to standard causes with
ts compensatory hyperadrenergic and FFA responses may
nduce a wide variety of metabolic changes that, together
ith increasing insulin resistance, may deteriorate into a
econdary insulin-resistant cardiomyopathy (1). The aim of
etabolic therapy is to inhibit or delay this adverse se-
uence. In this paper we briefly review normal and abnormal
lucose-fatty acid interactions that lead to the adverse
etabolic effects of high FFA concentration and to insulin
esistance. We then outline procedures whereby less-adverse
atty acid metabolism and a more favorable carbohydrate
etabolism and decreased oxygen wastage (Fig. 1) can be
chieved in patients with HF. However, it is not just a case
f lessening circulating FFA and thereby improving myo-
ardial function, as shown by the adverse effects of rapid
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Adrenergic-Fatty Acid Load in HF October 27, 2009:1637–46FFA reduction (13), but rather of
taking into account the action of
inhibitors of free fatty acid oxi-
dation (FAO) on extracardiac
sites such as skeletal muscle (14).
Furthermore, hyperglycemia also
needs to be controlled.
Substrate Competition
in the Heart
Randle’s glucose-fatty acid cycle.
The heart relies almost exclu-
sively on aerobic oxidation of
substrates to generate ATP,
which is required to maintain its
cellular and contractile functions.
A keen interest in the substrate
supply in human HF dates back
more than 50 years to the pio-
neering work of Blain et al. (15).
The primary substrates metabo-
lized by the myocardium are
FFAs, glucose, lactate, and, to a
lesser extent, amino acids (16,17).
The myocardial substrate usage
varies considerably throughout
he day, depending on substrate availability, nutritional
tatus, and exercise level. This variation forms the basis of
he glucose-fatty acid cycle as first proposed by Randle et al.
4) in isolated heart and diaphragm muscle and later
onfirmed by Nuutila et al. (18) in the human heart and
keletal muscle. In the fasted state, when blood levels of
FAs are elevated, assuming that coronary flow and oxygen
Abbreviations
and Acronyms
AMPK  adenosine
monophosphate-activated
kinase
ATP  adenosine
triphosphate
CoA  coenzyme A
FAO  free fatty acid
oxidation
FFA  free fatty acid
GLUT  glucose
transporter
HF  heart failure
LV  left ventricular
NE  norepinephrine
PKC  protein kinase C
PPAR  peroxisome
proliferator-activated
receptor
ROS  reactive oxygen
species
TMZ  trimetazidine
UCP  uncoupling protein
Figure 1 FFA Effects on Mitochondria
High circulating levels of free fatty acid (FFA), activated within the muscle cell
to fatty acid-coenzyme A (CoA), enter the mitochondria by the action of carni-
tine palmitoyl transferase (CPT)-1, thereby inhibiting the action of pyruvate
dehydrogenase (PDH), blocking protective glycolysis that supplies cytosolic
adenosine triphosphate used for ion pumps, and decreasing glucose uptake by
muscle. Excess activated FFA increases the formation of reactive oxygen spe-
cies. For oxygen wastage, see Figure 2. FAO  free fatty acid oxidation.Fupply are normal, FFAs are the major source of energy
70%), for the myocardium ATP is formed by oxidative
etabolism of FFAs, which inhibits glycolysis and glucose
xidation at several sites but chiefly at the level of pyruvate
ehydrogenase (17), so that the decreased amount of glu-
ose taken up is converted to glycogen (4,7,16). In the case
f glucose, the contribution to the energy needs of the heart
ight vary from 10% after a fat meal to 70% after a
arbohydrate meal. Lactate concentrations, when high as
uring heart perfusion or exercise, inhibit the uptake of
FAs and the oxidation of glucose (19–21). Triglyceride,
fter conversion to FFA by lipoprotein lipase, can account
or 50% of the myocardial oxidative metabolism after an
ntravenous lipid load or post-prandial lipemia (22).
With this background, the excessive beta-adrenergic–
riven excess mobilization of FFA in HF is likely to switch
ff glucose oxidation to obliterate most or all of the diurnal
lucose-fatty acid cycling. Stated differently, we postulate
hat advanced HF would inhibit the physiological function-
ng of the Randle cycle. Of note, genetically induced
yocardial lipid overload leads to cardiomyopathy (23).
onversely, cardiac-specific increased glucose uptake in-
uced by overexpression of a glucose transporter prevents
ressure-induced HF (24).
FA-induced oxygen wastage. It is known that FAO is less
nergy efficient than glucose, requiring 11% to 12% more
xygen for a given amount of ATP produced (16). In addition,
t is important to note that the amount of ATP synthesized per
ole of oxygen consumed is dependent on the coupling of
roton influx and ATP production in the mitochondria. Thus,
ith high levels of circulating FFA, the actual amount of ATP
roduced by FAO may be much lower than expected (11).
hus, when FAO is driven by marked elevation of FFAs by
ipid infusions given to dogs, the myocardial oxygen uptake
ncreased by about 20%, whereas with high degrees of adren-
rgic activation by norepinephrine (NE) infusions, the meta-
olic component of the myocardial oxygen uptake can be
alculated to be about 50% (Table 1) (9,10,25–28). Of much
nterest, this large increase in the myocardial oxygen uptake
ould largely be reversed by the administration of high-dose
ntravenous glucose (10), strongly suggesting that there was
FA-induced oxygen wastage.
These data are compatible with the hypothesis that high
irculating FFA levels have adverse mitochondrial effects,
ncluding substantial oxygen wastage (Fig. 2). Nonetheless,
aution is required because the FFA-induced increases were
xtreme. In the human atrial myocardium from the failing
uman heart, the activity of uncoupling protein (UCP)-2
nd -3 is substantially increased at high levels of plasma
FA, whereas the glucose transporter (GLUT)-4 decreases
n activity (29). In diabetic mice high plasma FFA levels are
ssociated with increased UCP-3 levels (30). There are
everal proposed molecular mechanisms for uncoupling
17). Thus, increased levels of UCPs can be linked to
xygen wastage induced by excessive circulating levels of
FAs (Fig. 2), even though UCPs basically have a physio-
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October 27, 2009:1637–46 Adrenergic-Fatty Acid Load in HFogical role (31). Our proposal is that similar changes occur
n the hyperadrenergic state in HF to worsen HF by
roducing a metabolic vicious circle (32). However, it
hould be appreciated that the relationship between mito-
hondrial oxidation of activated fatty acids and uncoupling
s extremely complex (33). On the one hand, an increased
upply and oxidation of activated fatty acids promotes ROS
ormation to exaggerate mitochondrial dysfunction. Such
OS are derived from FFA-driven mitochondrial sources at
omplexes I and III (Fig. 2) (34). Furthermore, incomplete
AO may lead to intramitochondrial accumulation of acyl-
oenzyme A (CoA), which damages mitochondria (35). On
he other hand, mitochondrial UCPs can export activated
atty acids to decrease the degree of uncoupling of respira-
ion and hence to decrease lipotoxicity. Presumably, in HF
ffect of FFA on MVO2Table 1 Effect of FFA on MVO2
Ref. # Measure Preparation
25 MVO2 (unloaded) In situ pig heart, coronary sinus
catheterization
9 MVO2 In situ dog heart
10 MVO2 In situ dog heart
26 MVO2 Isolated working perfused rat heart
27 MVO2 Isolated working perfused rat heart
28 Myocardial efficiency of work Open chest pig
pi  epinephrine; FFA  free fatty acid; GIK  glucose, insulin, potassium; Iso  isoproterenol;
Figure 2 Mitochondrial Sources of ROS
As protons are passed along the electron transport chain, reactive oxygen species
uncoupling proteins, which divert protons form ATP formation and, hence, waste o
ADP  adenosine diphosphate; ATP  adenosine triphosphate; FA  fatty acid; ohe hyperadrenergic state and the associated excess FFA
upply override any self-protective mechanisms.
eduction in FFA Metabolism as Therapy for HF
top it at the start: inhibit excess adrenergic activity. In-
reased plasma NE levels in patients with HF were first
escribed by Chidsey et al. (36) in 1962. The degree of
levation is closely related to the severity of the HF (2), with
ery high NE levels found in advanced untreated HF (3,37),
ompatible with the proposal that NE release is a compen-
atory phenomenon to sustain the decreasing blood pressure
s cardiac failure progresses. The increased plasma levels of
E reflect both reduced clearance and markedly increased
E spillover from the heart and kidneys, so that there must
Intervention Change
nfusion of intralipid heparin versus GIK MVO2 increase of 48%
nfusion of intralipid heparin MVO2 increase by 26%
nfusion of Iso  glucose MVO2 increase by 91% after Iso,
down to 45% after glucose;
FFA-induced increase of 50%
pi 106 mol/l added to glucose
perfusate
MVO2 increased by 72% by Epi;
reduced to 34% after nicotinic acid
nergy metabolism changed from
carbohydrate to palmitate oxidation
MVO2 increased by about 30%
nfused glucose to 12 mmol/l Efficiency of work increased by 32%
myocardial oxygen uptake.
) are formed at complexes I and III. FFA-induced proton leakage passes through
Modified, with permission, from Opie (16). Figure copyright of L. H. Opie.
breviations as in Figure 1.I
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Adrenergic-Fatty Acid Load in HF October 27, 2009:1637–46e increased sympathetic neural discharge (38). In a dog
odel of chronic HF, as the plasma NE increased, so did
lasma FFA, insulin, and glucose (3), indicating the
drenergic-induced development of insulin resistance (Fig. 3).
he basic remedy is to fix the cause, which is to counter the
ailing myocardium by any unloading step, including diuresis
nd renin-angiotensin inhibition. Improved mechanical func-
ion by cardiac resynchronization also should decrease plasma
E and FFA levels.
eta-blockade indirectly inhibits FFA metabolism. Long-
erm therapy with beta-adrenergic receptor antagonists is
nown to improve left ventricular (LV) function and sur-
ival in patients with HF (Fig. 4) (39–42). Noninvasive
tudies (40,41) in which the authors used beta-blocker
herapy demonstrated a significant decrease in oxidative
etabolism and improved myocardial efficiency in HF
atients after the intervention period. These improvements
n myocardial energetics suggest that beta-blocking agents
ave an energy-sparing effect in HF patients that may be
ue to a switch in myocardial substrate preference away
rom FAO toward carbohydrate oxidation (40,43). Further-
ore, after 3 months of treatment with metoprolol, LV
unction and myocardial efficiency improved as carbohy-
rate use increased (44). With another beta-blocker, carve-
ilol, also administered for 3 months, myocardial FFA
ptake was decreased by 57% in patients with New York
eart Association functional class III HF (41). In 8 of the
patients, myocardial glucose uptake increased, although
his finding was not statistically significant. Beta-blockade
Figure 3 Pacing-Induced DCM in Dogs
Changes in circulating norepinephrine (NE), free fatty acids (FFAs), insulin, and glu
increases in FFA and NE. Modified from Nikolaidis et al. (3) with permission of Oxflso reduced the rate of myocardial oxidative metabolism as aeasured with 11C-acetate and positron emission tomogra-
hy (40).
More recently, in the only prospective metabolic study
45) that directly compared carvedilol with metoprolol, 11
atients with HF were treated for 4 months with either
gent with similar hemodynamic responses. Metabolically,
nly carvedilol shifted substrate use from FFA to lactate
xtraction. These metabolic differences between carvedilol
nd metoprolol may help to explain why carvedilol was
etter at reducing the rate of mortality in a large definitive
rial on patients with HF (46).
cute FFA reduction by acipimox. If FFAs constitute
uch a serious problem in patients with HF, the logical step
ould be to reduce the FFA levels which, in turn, should
mprove glucose metabolism. We have undertaken 2 sepa-
ate studies (13,14) to assess the ideal means of lowering
FAs. Acipimox, a nicotinic acid derivative, when given as
n acute antilipolytic agent to patients with idiopathic
ardiomyopathic HF, acutely decreased myocardial FFA
ptake by more than 80% which, in those patients with
ealthy hearts, was accompanied by a decrease in oxidative
etabolism, in keeping with the concept of FFA-induced
xygen wastage (13). However, in patients with failing
earts, acute FFA depletion did not down-regulate oxida-
ive metabolism, and myocardial efficiency of work de-
reased. Thus, unexpectedly, these hearts were more depen-
ent on FFA metabolism than normal hearts, which led to
aegtmeyer and Ballal’s (47) concept that metabolic ex-
remes can cause lipotoxicity or glucotoxicity, both of which
ith progressive heart failure. Note major
iversity Press. DCM  dilated cardiomyopathy.cose w
ord Unre adverse for the failing heart.
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October 27, 2009:1637–46 Adrenergic-Fatty Acid Load in HFrimetazidine (TMZ) for HF. Trimetazidine is a meta-
olically active antianginal widely used in Europe but not
icensed in the U.S. It has multiple potentially cardiopro-
ective mechanisms besides partial inhibition of FAO with
ncreased glucose oxidation as found in isolated rat hearts
Online Table 1). In patients with type 2 diabetes and HF,
TMZ-induced increase in muscle glucose oxidation and
ecreased FAO (measured by citrate release) occurred in the
orearm muscle (48).
In our clinical studies with TMZ given for chronic HF,
he hypothesis was that partial inhibition of myocardial
AO by the heart would result in improved mechanical
unction (14). Although the use of TMZ had previously
een tested in patients with HF and found to be effective in
Figure 4 Sites of Metabolic Interventions in HF
FFAs are mobilized from adipose tissue to inhibit the uptake of glucose by
muscle (including heart muscle). The result is hyperglycemia and increased
insulin resistance. Elevated FFAs also act on mitochondria (mito) to cause
excess oxygen wastage with formation of ROS (42). The consequences include
mitochondrial and cellular dysfunction (ionic changes, increased cell calcium
and sodium). Metabolic interventions decrease insulin resistance, hyperglyce-
mia, and ROS formation to decrease the severity of heart failure. Abbreviations
as in Figures 1 and 2.studies (12), there were no studies in which the authors pirectly measured the postulated decrease in myocardial
AO (Online Appendix). Our study was the first to directly
easure FAO by the heart and the first to study chronic HF
aused by idiopathic dilated cardiomyopathy in patients
ithout any overt clinical myocardial ischemia. When TMZ
as given, the ejection fraction of patients with HF group
ncreased modestly (14). However, myocardial fatty acid
ptake was unchanged, and the rate of FAO decreased by
nly 10%, which we proposed was probably not the major
ite of TMZ action. Whole-body insulin resistance de-
reased, confirming the findings in patients with diabetic
F (48). For the first time in studies with TMZ we
eported that fasting plasma high-density lipoprotein con-
entrations increased by 11%, presumably reflecting de-
reased insulin resistance (49). By virtue of its sphingosine-
-phosphate content, high-density lipoprotein has direct
xperimental cardioprotective effects (50). The change in
jection fraction induced by TMZ highly correlated with
he beta-1 receptor occupancy, suggesting a synergistic
nteraction between the general metabolic changes achieved
y TMZ and the degree of beta-1 receptor blockade already
art of the therapy (14).
Hypothetically, decreased FFA and increased glucose
xidation in the failing human heart and skeletal muscle
ould decrease FFA- and hyperglycemia-associated oxida-
ive stress. Of note, normalizing excess ROS counters
athways of hyperglycemic damage (51). However, no
MZ-induced effect on cardiac glucose oxidation in human
F has yet been measured.
erhexiline for HF. Perhexiline is a partial inhibitor of
AO, inhibiting the mitochondrial uptake of FFA by the
nzyme carnitine palmitoyl transferase-1 (Fig. 2). There is
nly 1 HF study (52) in which the authors reported the
enefits of perhexiline in HF. When added to the previous
herapy, while blood levels were monitored to avoid hepa-
oxicity, the authors found that perhexiline improved peak
xercise-induced oxygen uptake, enhanced the quality of
ife, and increased the LV ejection fraction (52). Perhexiline
lso normalized the post-exercise recovery of phosphocre-
tine in skeletal muscle. This study lends strong support to
he concept that inhibition of FAO is beneficial in HF
ecause of concordance with basic science studies and the
nique mechanism of action on one mitochondrial enzyme,
n contrast to the many diverse effects reported for TMZ.
owever, there are no direct measurements of perhexiline
nhibition of cardiac FAO in human HF. Hepatotoxicity
topped a clinical trial with etoxomir, another inhibitor of
arnitine palmitoyl transferase-1 (12).
anolazine for HF. Ranolazine, a compound that struc-
urally resembles TMZ, originally was regarded as an agent
ith metabolic effects consonant with the benefits of a shift
rom fatty acid to glucose metabolism in ischemic rat hearts
53). In agreement with these metabolic changes in rodent
earts, there is improved glycemic control as shown by the
ersistent decrease in the HbA1c levels when ranolazine is
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Adrenergic-Fatty Acid Load in HF October 27, 2009:1637–46iven to patients with chronic angina and diabetes (54) or to
hose with acute coronary syndrome (55).
Some recent author data (56) question the role of
nhibition of fatty acid oxidation as the major site of
anolazine action and rather suggest (57) that ranolazine
nhibits the late sodium inward current. Because myocardial
odium overload occurs in the failing heart, it is not
urprising that ranolazine, combined with enalapril or
etoprolol, limits progressive LV dysfunction in dogs with
oderate chronic HF (58). Sodium overload is responsible
or a secondary calcium overload by the sodium/calcium
xchange mechanism, compatible with the finding that
anolazine improves diastolic function in isolated myocar-
ium from failing human hearts (57). In the latter study,
here was direct evidence for inhibition of the late sodium
urrent by ranolazine. However, there are no definitive
tudies on the effects of ranolazine in human HF.
echanisms That Stimulate Adenosine
onophosphate-Activated Kinase (AMPK) Activity
MPK is the cellular sensor that responds to situations of
TP breakdown, such as exercise. Because of the high
TP-to-adenosine monophosphate ratio in muscle cells,
he breakdown of only a small amount of ATP considerably
ncreases adenosine monophosphate levels to activate
MPK. When this enzyme is activated, it stimulates both
Figure 5 Site of Action of Metformin
Molecular steps leading from increased FFA to insulin resistance. Excess FFA ente
naling pathway so that there is less translocation of glucose transporter vesicles (
promoted. The increased uptake of FFA promotes the accumulation of lipid metab
stimulating adenosine monophosphate-activated kinase (AMPK), promote the trans
oppose insulin resistance. Protein kinase B (PKB), also called Akt, plays a key role
lin receptor substrate; P-I-3  phosphoinositide-3; other abbreviations as in Figurehe oxidation of FFA and the uptake of glucose (Fig. 5). phe mechanism whereby activation of AMPK increases
atty acid oxidation is complex. AMPK phosphorylates and
ctivates the enzyme acetyl-CoA carboxylase, which in turn
ecreases malonyl-CoA activity, thereby lessening the nor-
al inhibition that malonyl-CoA exerts on transport of
ctivated long chain fatty acid into myocardial cells (17).
he glucose effect results from increased migration of
lucose-transporting vesicles (GLUT-1 and -4) to the
arcolemma to promote glucose uptake. Hypothetically,
hese effects could either benefit or harm patients with HF.
ncreased glucose uptake and oxidation would accord with
he basic hypothesis proposed here, namely that promotion
f glucose metabolism might be beneficial in patients with
F. Conversely, however, increased fatty acid oxidation
ould be expected to have adverse effects on mitochondrial
TP production (Fig. 2).
xercise. Exercise in those with insulin resistance and
re-diabetes lessens the development of new diabetes (59).
n relation to the therapy of HF, the protective glucose-
ediated effects seem to dominate any adverse FFA-
ediated effects. In HF, exercise training reduces insulin
esistance (60) and increases skeletal and cardiac glucose
ptake, probably by activating the insulin-insensitive
LUT-1 transporters (61,62). At least part of the benefit of
xercise in HF patients, which includes mortality reduction
63), could be mediated by similar mechanisms. This
e muscle cell is activated to long-chain acyl-CoA, which inhibits the insulin sig-
and -1) to the cell surface. Glucose uptake is decreased and hyperglycemia
n various organs, including the heart and pancreas. Metformin and exercise, by
on of transport vesicles to the cell surface to promote glucose entry and to
ified, with permission, from Opie (16). Figure copyright of L. H. Opie. IRS  insu-ring th
GLUT-4
olites i
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October 27, 2009:1637–46 Adrenergic-Fatty Acid Load in HFatients with dilated cardiomyopathy already treated by
eta-blockade was accompanied by enhanced forward work
fficiency and decreased cardiac oxidative metabolism (64).
etformin. Besides stimulating AMPK to increase myo-
ardial glucose uptake (Fig. 5), metformin decreases hepatic
ynthesis of fatty acids and of glucose (65,66). Experimen-
ally, it has protective effects in experimental HF acting via
MPK (67,68). In patients with type 2 diabetes and HF,
here were reduced deaths and hospital readmissions with
etformin versus other glucose-lowering therapies (69).
owever, despite the stimulatory effect on AMPK, met-
ormin could not further increase glucose uptake by skeletal
uscle in exercising diabetic patients (70), suggesting that
he exercise had already maximally stimulated muscle
MPK activity. In resting nonobese patients with type 2
iabetes, metformin considerably increases peripheral blood
ow and uptake of glucose by muscle while decreasing blood
FA levels (71). Why do FFA levels decrease? One mech-
nism could be that metformin counters the direct toxic
ffect of FFA on human isolated pancreatic islets (72),
hich should decrease insulin resistance. Overall, prospec-
ive controlled trials with metformin in human HF are
equired.
diponectin. Adiponectin is an adipokine that interacts
ith and mimics some of the metabolic effects of insulin
73). Key among its intracellular reactions is activation of
MPK (73). Decreased adiponectin levels as found in
iabetes, metabolic syndrome, and coronary artery disease
ay contribute to insulin resistance. Adiponectin counter-
cts the effects of increased FFA levels that promote
ndothelial dysfunction and insulin resistance (73), both
allmarks of HF. However, despite the activation of AMPK
y adiponectin, there is no direct clinical evidence of a
trong relationship between adiponectin and HF. In the
ramingham Offspring Study (74), adiponectin was not
ssociated with the development of new HF but, instead,
esistin, another adipokine, was linked with HF. Of inter-
st, epicardial fat is a newly identified source of adipokines,
oth pro- and anti-inflammatory (75), without as yet any
irect relation to HF.
iet, Insulin, and Hyperglycemia
iet and HF. As already explained, the human heart
erives energy from glucose, fatty acids, and/or lactate
epending upon substrate availability and nutritional status.
n patients who are physically inactive, who are obese, and
ho have type 2 diabetes, circulating FFA and glucose levels
ften exceed the normal range, with risks of lipotoxicity and
lucotoxicity possible (76). Emerging data (76) suggest that
ubstrate excess leading to cardiac dysfunction and HF may
e prevented or slowed by maintaining low body fat and
igh insulin sensitivity and by consuming a diet of low
lycemic load that is high in monounsaturated and polyun-
aturated fatty acids. At present, it is unclear whether this cew nutritional paradigm will be effective in the prevention
r treatment of HF.
nsulin to control FFA, glycemia, and inflammatory
arkers? Besides the risk of FFA-induced deterioration of
yocardial dysfunction in HF, a further risk is insulin
esistance, which is highly prevalent in nondiabetic patients
ith HF (14,49) and sometimes severe enough to promote
nd cause the diabetic state (1). A striking feature of the
esponse of the normal heart to injury is the reactivation of
he fetal gene program that promotes glucose metabolism
nd lessens that of FFA. Gene-induced changes include
ecreased UCPs, thereby increasing the generation of ATP
1,77). Conversely, FFAs induce the transcription factor
eroxisome proliferator-activated receptor (PPAR)-alpha
hat promotes FAO. When PPAR-alpha is pharmacologi-
ally activated, then the hypertrophied heart starts to fail
78), presumably as a result of excess FAO.
The inflammatory response is promoted both by hyper-
lycemia and high FFA levels (8,79). Superoxide produc-
ion activates proinflammatory transcription factors and
educes the availability of nitric oxide (8,79). In diabetic
atients, post-prandial hyperglycemia is associated with
ncreased plasma C-reactive protein values (80). Thus,
ontrol of hyperglycemia and high FFA levels by insulin
hould be beneficial in HF both by metabolic effects and by
ampening the inflammatory response.
an insulin benefit human HF? Short-term animal stud-
es link high FFA levels to substantial oxygen wastage in a
ariety of preparations, with evidence for the energetic
enefit of glucose (Table 1). Yet, we still lack detailed
uman studies with insulin in HF, although the concept was
roposed nearly 40 years ago (81). Regarding intensive
lucose control for acutely ill patients, the newly available
ata (82,83) show harm rather than benefit, probably caused
y episodes of dangerous hypoglycemia, thus supporting the
iew that the metabolic management of the acutely ill
ardiac patient extends beyond control of hyperglycemia
84). We also stress the potential danger of an insulin-
nduced acute reduction in FFA metabolism (85), which
ould decrease cardiac efficiency and work as with acipimox
13). The present trend is to explore the use of incretins (see
he next section).
osiglitazone and pioglitazone: PPAR-gamma activators.
he thiazolidinediones, also called the “glitazones,” are
rugs that activate the PPAR-gamma transcriptional sys-
em, thereby promoting the metabolism of glucose. These
ompounds also have anti-inflammatory effects and increase
oncentrations of adiponectin (86). Although known to
ncrease myocardial glucose uptake in patients with type 2
iabetes (87,88), likely partly the result of reduction in
irculating FFA concentrations, these agents also can pre-
ipitate fluid retention and hence HF. In the PROactive
PROspective PioglitAzone Clinical Trial In MacroVascu-
ar Events) trial, pioglitazone administered to patients with
ype 2 diabetes reduced serious cardiovascular events, in-
luding myocardial infarction and stroke, while substantially
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ersons lessened the incidence of new diabetes, but the
ncidence of new HF increased (90). A proposed mecha-
ism is that the PPAR-gamma activity acts on the distal
ephron to promote sodium and fluid retention (91), which
n the presence of lipid-induced incipient diastolic HF (92)
an precipitate congestive HF (93) despite enhanced myo-
ardial glucose uptake (87). Thus, a presumed beneficial
vent, increased glucose uptake by the heart (87,88), is
verridden by the propensity to cause HF by renal sodium
etention.
uture Metabolic Therapies for HF
alonyl-CoA activity. Carnitine palmitoyl transferase-1
s a key enzyme that not only is inhibited by perhexiline, but
s the “gatekeeper” of mitochondrial fatty acid uptake, it is
hysiologically controlled by varying degrees of inhibition
y malonyl-CoA. Physiologically, AMPK kinase indirectly
egulates FAO by phosphorylation of acetyl-CoA carboxy-
ase, which lowers malonyl-CoA levels (17). Thus, a novel
pproach to inhibit excess FFA uptake by mitochondria
ould be to increase the activity of malonyl-CoA by
nhibiting the enzyme, breaking it down (malonyl-CoA
ecarboxylase) (94). The consequent metabolic shift away
rom fatty acid oxidation toward increased glucose oxidation
hould benefit the failing myocardium. Such compounds are
ow under development and may become ready for early
linical trials initially targeting ischemic/reperfusion injury.
mega-3 fatty acids. High fish intake, correlating with
evels of plasma omega-3 fatty acids, was associated with
ecreased incident HF in an elderly population study (95).
xperimentally, rats treated by omega-3 polyunsaturated
atty acids in a dose range similar to that of humans taking
uch supplements were more resistant to the adverse effects
f aortic banding with less ventricular dilation (96). The
roposed mechanistic benefits are increased plasma adi-
onectin and decreased inflammatory markers. Preliminary
uman studies to treat HF metabolically by docosahexae-
oic acid are planned.
rotein kinase C (PKC)-epsilon. Proteomic and metabo-
omic analyses recently have shown that PKC-epsilon ac-
ivity modulates cardiac glucose metabolism and lessens
schemic/reperfusion damage, whereas PKC-delta has the
pposite effects (97). A selective inhibitor of PKC-delta has
een given to patients with acute myocardial infarction.
esting in HF is awaited.
lucagon-like peptide-1. This incretin increases myocar-
ial glucose uptake with the advantage over insulin that it
voids hypoglycemia. In 12 patients with advanced HF, a
-week infusion added to standard therapy improved LV
jection fraction, quality of life, and walking distance (98).
onclusions
eart failure is associated with major metabolic changes
hat include the consequences of the hyperadrenergic stateith increased circulating plasma FFAs, impaired glucose
etabolism, hyperglycemia, and increased insulin resis-
ance. We have reviewed data supporting the hypothesis
hat cardiac and whole-body metabolic changes occur with
he development of HF. Increased FFA-induced mitochon-
rial UCP activity is closely associated with the generation
f ROS and inflammatory markers. Beta-blockade acts
etabolically to decrease myocardial FFA uptake and in-
rease work efficiency. Three antianginal drugs, TMZ,
erhexiline, and ranolazine, all have data favoring their use
r testing in HF, whether ischemic or nonischemic in
rigin. The metabolic effects of exercise are beneficial.
owever, care should be exercised when thiazolidinediones
glitazones) are given to patients with type 2 diabetes,
espite positive effects on myocardial substrate metabolism.
he detailed mechanisms whereby these different metabolic
actors are linked to the development and therapy of HF are
ot yet elucidated.
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APPENDIX
or a table on the cardioprotective basic and clinical studies with
MZ and related references, please see the online version of this article.
